Soluble receptor for advanced glycation end products (sRAGE) as a biomarker of COPD

Pratte, Katherine A.; Curtis, Jeffrey L.; Kechris, Katerina; Couper, David; Cho, Michael H.; Silverman, Edwin K.; DeMeo, Dawn L.; Sciurba, Frank C.; Zhang, Yingze; Ortega, Victor E.; O’Neal, Wanda K.; Gillenwater, Lucas A.; Lynch, David A.; Hoffman, Eric A.; Newell, John D.; Comellas, Alejandro P.; Castaldi, Peter J.; Miller, Bruce E.; Pouwels, Simon D.; Hacken, Nick H. T. t.; Bischoff, Rainer; Klont, Frank; Woodruff, Prescott G.; Paine, Robert; Barr, R. G.; Hoidal, John; Doerschuk, Claire M.; Charbonnier, Jean-Paul; Sung, Ruby; Locantore, Nicholas; Yonchuk, John G.; Jacobson, Sean; Tal-singer, Ruth; Merrill, Debbie; Bowler, Russell P.

Soluble receptor for advanced glycation end products (sRAGE) is a proposed emphysema and airflow obstruction biomarker; however, previous publications have shown inconsistent associations and only one study has investigate the association between sRAGE and emphysema. No cohorts have examined the association between sRAGE and progressive decline of lung function. There have also been no evaluation of assay compatibility, receiver operating characteristics, and little examination of the effect of genetic variability in non-white population. This manuscript addresses these deficiencies and introduces novel data from Pittsburgh COPD SCCOR and as well as novel work on airflow obstruction. A meta-analysis is used to quantify sRAGE associations with clinical phenotypes.

sRAGE was measured in four independent longitudinal cohorts on different analytic assays: COPDGene (n = 1443); SPIROMICS (n = 1623); ECLIPSE (n = 2349); Pittsburgh COPD SCCOR (n = 399). We constructed adjusted linear mixed models to determine associations of sRAGE with baseline and follow up forced expiratory volume at one second (FEV1) and emphysema by quantitative high-resolution CT lung density at the 15th percentile (adjusted for total lung capacity).

Lower plasma or serum sRAGE values were associated with a COPD diagnosis (P < 0.001), reduced FEV1 (P < 0.001), and emphysema severity (P < 0.001). In an inverse-variance weighted meta-analysis, one SD lower log10-transformed sRAGE was associated with 105 ± 22 mL lower FEV1 and 4.14 ± 0.55 g/L lower adjusted lung density. After adjusting for covariates, lower sRAGE at baseline was associated with greater FEV1 decline and emphysema progression only in the ECLIPSE cohort. Non-Hispanic white subjects carrying the rs2070600 minor allele (A) and non-Hispanic African Americans carrying the rs2071288 minor allele (A) had lower sRAGE measurements compare to those with the major allele, but their emphysema-sRAGE regression slopes were similar.

Lower blood sRAGE is associated with more severe airflow obstruction and emphysema, but associations with progression are inconsistent in the cohorts analyzed. In these cohorts, genotype influenced sRAGE measurements and strengthened variance modelling. Thus, genotype should be included in sRAGE evaluations.


  • thumnail for 12931_2021_Article_1686.pdf 12931_2021_Article_1686.pdf application/pdf 472 KB Download File

Also Published In

Respiratory Research

More About This Work

Published Here
September 22, 2023


COPD, Emphysema, Biomarkers, Progression